Preparation of drug-loaded microspheres with magnetic resonance visualization microwave sensitization
By using nanomanganese dioxide microspheres in liver cancer treatment, combined with magnetic resonance visualization and microwave sensitization technology, the problems of ablation range and drug distribution monitoring in liver cancer treatment are solved, and efficient liver cancer treatment and monitoring are achieved.
Patent Information
- Application Number
- CN202410962301.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
AI Technical Summary
Existing treatment methods for liver cancer such as hepatic artery chemoembolic and microwave ablation have problems such as limited ablation range, poor conformity, repeated treatment, and difficulty in completely killing tumor cells, and lack effective drug targeting and distribution monitoring methods.
Nanomanganese dioxide microspheres with magnetic resonance visualization function are used to improve microwave ablation efficiency by loading metal salts and drugs, and achieve slow-controlled release and self-degradation of drugs in a tumor environment, and real-time monitoring of distribution in combination with magnetic resonance imaging function.
It significantly improves the range and efficiency of tumor microwave ablation, realizes targeted controlled release of drugs and continuously kills tumor cells, enhances the thoroughness and monitoring capabilities of treatment, and provides a more efficient comprehensive treatment plan for liver cancer.
Smart Images

Figure CN118903438A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biomedical engineering, and in particular to the preparation of drug-loaded microspheres with magnetic resonance visualization and microwave sensitization. Background Art
[0002] Primary liver cancer is a common malignant tumor in my country. Surgical resection is the first choice for early liver cancer treatment. However, most liver cancers are discovered in the middle and late stages and have lost the opportunity for surgery. Interventional therapy is the main treatment for these patients. Hepatic artery embolization can cut off the blood supply of liver tumors, causing tumor cells to die due to ischemia while the rest of the liver is not affected. However, due to the limitations of the safe dose of embolic agents and chemotherapy drugs and the influence of factors such as vascular recanalization, this method cannot completely necrotize liver cancer cells, so repeated treatments are required.
[0003] Microwave ablation is to place the ablation needle into the tumor through percutaneous puncture under the guidance of B-ultrasound or CT. The microwaves emitted by the ablation needle make the molecules in the surrounding tissue vibrate, rub against each other to generate heat, and increase the temperature of the tissue. When the temperature rises to about 60°C, the cell protein denatures and coagulates, leading to irreversible necrosis, thus achieving the purpose of killing the tumor. This method has the advantages and characteristics of safety, reliability, simple operation, good efficacy, and rapid postoperative recovery. However, microwave ablation still has its defects, namely, the ablation range is limited, the conformality is poor, and the ablation of larger tumors is not complete; local recurrence caused by residual tumor cells after microwave ablation has become one of the important factors affecting the medium- and long-term efficacy of microwave ablation treatment of liver cancer; in addition, repeated treatment of larger tumors not only increases the economic burden, but may also cause damage to a larger range of surrounding normal liver tissue.
[0004] It is difficult to achieve complete tumor necrosis with hepatic arterial chemoembolization alone, while simple ablation has the disadvantages of limited ablation range and poor conformality. It has been proven that the combination of the two can effectively improve the treatment effect. Using arterial embolization to embolize the main blood supply vessels can reduce or block blood flow, and then microwave ablation can reduce heat loss and obtain higher thermal ablation efficiency, thereby improving the efficacy.
[0005] Some scholars have shown that for liver tumors larger than 5 cm that are not suitable for surgical treatment, the median survival of hepatic artery chemoembolization alone is 13 months, and after combining with microwave ablation, the median survival is extended to 25 months, indicating that microwave ablation combined with hepatic artery chemoembolization has more advantages. Therefore, if the three technologies of tumor embolization, microwave ablation, and controlled release of chemotherapy drugs are organically combined, it is expected to further improve the treatment level of liver cancer.
[0006] The rapid development of nanotechnology and nanomaterials has provided technical reserves for finding more efficient liver cancer embolization, microwave ablation, and controlled release of chemotherapy drugs. Embolic microspheres combined with nanotechnology have shown great potential in the interventional treatment of tumors, but the relevant technology is still in the primary research stage and there are still many problems, such as unsatisfactory heating effect and difficulty in detection, so further research is needed. Summary of the invention
[0007] The purpose of the present invention is to provide a preparation method for drug-loaded microspheres with magnetic resonance visualization and microwave sensitization. The drug carrier of the present invention can improve the warming effect of embolic microspheres and detect the distribution of embolic microspheres in tumors and in vivo.
[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0009] The invention provides a drug carrier, comprising hollow nano manganese dioxide and a metal salt loaded on the nano manganese dioxide.
[0010] Preferably, the metal salt comprises one or more of NaCl, NaF and CaCl2.
[0011] Preferably, the particle size of the nano manganese dioxide is 100-200 nm.
[0012] Preferably, the mass of the metal salt is 0.5-2% of the mass of the nano manganese dioxide.
[0013] The present invention also provides a method for preparing the drug carrier described in the above technical solution, comprising the following steps:
[0014] The drug carrier is obtained by mixing a metal salt, a polar organic solvent and hollow nano manganese dioxide and removing the polar organic solvent.
[0015] The present invention also provides an embolic microsphere, comprising a degradable skeleton, a drug carrier loaded on the skeleton, and a drug loaded on the drug carrier.
[0016] Preferably, the drug comprises doxorubicin.
[0017] Preferably, the backbone comprises poly(lactic-co-glycolic acid).
[0018] Preferably, the ratio of the total mass of the drug carrier and the drug to the mass of the degradable skeleton is 1:8-12.
[0019] The present invention also provides a method for preparing the embolic microspheres described in the above technical solution, comprising the following steps:
[0020] Dispersing the drug carrier loaded with the drug in water and then mixing it with the organic dispersion of the degradable skeleton for emulsification to obtain colostrum;
[0021] The colostrum is mixed with an aqueous solution of an emulsifier, and the water and the organic dispersion solvent are removed to obtain the embolic microspheres.
[0022] The invention provides a drug carrier, comprising hollow nano manganese dioxide and a metal salt loaded on the nano manganese dioxide.
[0023] Metal salts have high microwave heat conversion efficiency, and after being loaded on manganese dioxide, they are confined to a small space, which increases the collision of metal ions and heat transfer, and has a microwave thermal effect that is superior to that of the free state, greatly improving the microwave ablation efficiency of tumors at the embolization site; the hollow structure of nano manganese dioxide has a high specific surface area and mesoporous structure, a high porosity, can load a large amount of drugs, and has a unique MR imaging function; nano manganese dioxide can catalyze H2O2 in the tumor microenvironment to generate oxygen, can deplete reduced glutathione (GSH), reduce the consumption of reactive oxygen, achieve "increasing revenue and reducing expenditure" of ROS, and play a role in the targeted controlled release of ROS-sensitive drugs by regulating the level of ROS; at the same time, in the microenvironment of the tumor, nano manganese dioxide has a super-sensitive response disintegration characteristic to pH, which can achieve pH-sensitive drug sustained and controlled release, and continuously kill tumor cells after drug release to achieve a radical effect; more importantly, the degraded manganese ions can enhance magnetic resonance imaging, and the distribution of embolic microspheres prepared by drug carriers in the tumor and in the body can be monitored in real time through MR examination.
[0024] The present invention combines embolic microspheres with microwave ablation sensitization function with programmed active targeted nano-drug controlled release technology with MR imaging function, and obtains a multifunctional embolic microsphere with microwave sensitization, programmed targeted nano-drug controlled release, magnetic resonance T1-weighted imaging function of manganese ions, and self-degradation ability. The microwave sensitization function is realized by the loaded metal salt, which can increase the effect of tumor microwave ablation; the nano-drug particles with manganese dioxide nanoparticles as carriers are injected with manganese ions with magnetic resonance T1-weighted imaging function, and tumor diagnosis and treatment monitoring can be performed; the high temperature generated by microwave sensitization and the acidic microenvironment of the tumor can accelerate the degradation process of the multifunctional embolic microspheres, thereby realizing the self-degradation ability of the multifunctional embolic microspheres, and realizing the release of nano-drug particles from the multifunctional embolic microspheres and the release of drugs from the nano-drug particles.
[0025] The multifunctional embolic microspheres of the present invention achieve microwave ablation sensitization and programmed targeting in the following ways: 1) after being injected into the hepatic artery, the multifunctional embolic microspheres cause tumor vascular blood flow blockage, selectively stay in liver cancer tissue, and lead to insufficient blood supply to cancer tissue; 2) low-power microwaves are used for ablation, and the microwave-sensitive properties of metal salts are used in the embolic microspheres to achieve selective and efficient ablation of liver tumors and increase the ablation area; 3) the PLGA skeleton of the embolic microspheres is degraded under the heat generated by microwaves and the stimulation of the acidic microenvironment of the tumor, releasing functional unit nano drug particles; 4) the drug is gradually released from manganese dioxide, continuously killing the residual tumor cells inside and at the edge of the tumor, and achieving the effect of radical microwave treatment; 5) the MR imaging function of manganese dioxide is used to monitor the distribution changes of manganese dioxide inside the tumor before and after microwaves, so as to achieve highly specific diagnosis and treatment of tumors.
[0026] The multifunctional embolic microspheres constructed by the present invention can greatly improve the microwave heating efficiency in the tumor area, realize the controllability of the microwave ablation range, and work synergistically with the programmed targeted nano-chemotherapeutic drug controlled release technology to efficiently and thoroughly kill tumor cells. This new type of multifunctional embolic microspheres has opened up a new idea for interventional treatment of malignant tumors and provided new theories, strategies and technologies for comprehensive cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is an optical microscope image of PLGA@MnO2@(NaCl+DOX) microparticles in Example 1;
[0028] Figure 2 is the SEM image of PLGA@MnO2@(NaCl+DOX) microparticles in Example 1;
[0029] Figure 3 This is a statistical diagram of the size distribution of PLGA@MnO2@(NaCl+DOX) particles in Example 1;
[0030] Figure 4 Scanning electron microscope image of PLGA@MnO2@(NaCl+DOX) microparticles in Example 1 after storage at 37°C for 20 min, with the scale bar being 200 μm;
[0031] Figure 5 This is a scanning electron microscope image of the PLGA@MnO2@(NaCl+DOX) microparticles in Example 1 after being stored at 37°C for 20 minutes. The scale bar in the figure is 100 μm;
[0032] Figure 6 This is a scanning electron microscope image of the PLGA@MnO2@(NaCl+DOX) microparticles in Example 1 after being stored at 65°C for 20 minutes. The scale bar in the figure is 100 μm;
[0033] Figure 7 This is a scanning electron microscope image of the PLGA@MnO2@(NaCl+DOX) microparticles in Example 1 after being stored at 65°C for 20 minutes. The scale bar in the figure is 20 μm.
[0034] Figure 8 The temperature change curve of PLGA@MnO2@(NaCl+DOX) microparticles and normal saline in Example 1 under microwave irradiation;
[0035] Fig. 9 This is a thermal infrared imaging image of the mixture of PLGA@MnO2@(NaCl+DOX) microparticles and hydrogel in Example 1 under microwave irradiation. DETAILED DESCRIPTION
[0036] The invention provides a drug carrier, comprising hollow nano manganese dioxide and a metal salt loaded on the nano manganese dioxide.
[0037] In the present invention, the mass of the metal salt is preferably 0.5-2% of the mass of the nano manganese dioxide, more preferably 1.25-1.5%; the metal salt is harmless to the human body; the metal salt preferably includes one or more of NaCl, NaF and CaCl2; the particle size of the nano manganese dioxide is preferably 100-200nm. In the present invention, the metal salt preferably includes one or more of NaCl, NaF and CaCl2.
[0038] The particle size, core size, cavity volume, shell thickness, etc. of nano manganese dioxide can be designed and controlled as needed.
[0039] In the present invention, the preparation method of nano manganese dioxide preferably comprises the following steps:
[0040] Mixing NaHCO3 solution, MnSO4 and water to perform precipitation reaction to obtain MnCO3;
[0041] The MnCO3 and KMnO4 solutions are mixed to perform an oxidation-reduction reaction to obtain MnO2@MnCO3 having a core of MnCO3 and a shell of MnO2;
[0042] The MnO2@MnCO3 is mixed with a strong acid solution to perform double decomposition reaction, and MnCO3 is removed to obtain the nano manganese dioxide.
[0043] The present invention mixes NaHCO3 solution, MnSO4 and water and then performs precipitation reaction to obtain MnCO3.
[0044] In the present invention, the molar ratio of NaHCO3 to MnSO4 in the NaHCO3 solution is preferably 0.9-1:1; the concentration of NaHCO3 in the NaHCO3 solution is preferably 0.14 mol / L; and the volume ratio of the NaHCO3 solution to water is preferably 1:1.
[0045] In the present invention, the precipitation reaction is preferably carried out at room temperature, and the precipitation reaction time is preferably 3 hours; the precipitation reaction is preferably carried out under stirring conditions.
[0046] After the precipitation reaction, the present invention preferably performs solid-liquid separation on the product obtained by the precipitation reaction, and then washes and dries the obtained solid to obtain the MnCO3.
[0047] In the present invention, the solid-liquid separation method preferably includes centrifugation; the drying temperature is preferably 60° C., and the drying time is preferably 6 hours.
[0048] After obtaining MnCO3, the present invention mixes the MnCO3 with a KMnO4 solution to perform an oxidation-reduction reaction, thereby obtaining MnO2@MnCO3 having a core of MnCO3 and a shell of MnO2.
[0049] In the present invention, the ratio of the mass of the MnCO3 to the mass of the KMnO4 in the KMnO4 solution is preferably 1:1-1.5; the concentration of KMnO4 in the KMnO4 solution is preferably 0.032 mol / L.
[0050] In the present invention, the oxidation-reduction reaction is preferably carried out at room temperature, and the time of the oxidation-reduction reaction is preferably 3 hours; the oxidation-reduction reaction is preferably carried out under stirring.
[0051] After the oxidation-reduction reaction, the present invention preferably performs solid-liquid separation on the product obtained by the oxidation-reduction reaction, and then washes and dries the obtained solid to obtain the MnO2@MnCO3.
[0052] After obtaining MnO2@MnCO3, the present invention mixes the MnO2@MnCO3 with a strong acid solution to perform a double decomposition reaction, removes MnCO3, and obtains the nano manganese dioxide.
[0053] In the present invention, the strong acid solution preferably includes a hydrochloric acid solution; the concentration of the hydrochloric acid solution is preferably 0.1 mol / L.
[0054] The present invention has no particular limitation on the amount of the MnO2@MnCO3 and the strong acid solution, as long as the MnCO3 is fully removed.
[0055] In the present invention, the metathesis reaction is preferably carried out at room temperature, and the time of the metathesis reaction is preferably 4 hours; the metathesis reaction is preferably carried out under stirring conditions.
[0056] After the double decomposition reaction, the present invention preferably performs solid-liquid separation on the product obtained by the double decomposition reaction, and then washes and dries the obtained solid to obtain the nano manganese dioxide.
[0057] In the present invention, the solid-liquid separation method preferably includes centrifugation; the drying temperature is preferably 60° C., and the drying time is preferably 12 hours.
[0058] The present invention also provides a method for preparing the drug carrier described in the above technical solution, comprising the following steps:
[0059] The drug carrier is obtained by mixing a metal salt, a polar organic solvent and hollow nano manganese dioxide and removing the polar organic solvent.
[0060] In the present invention, the mass ratio of the metal salt to the volume ratio of the polar organic solvent is preferably 1 mg: 6 to 30 mL, more preferably 1 mg: 10 to 20 mL, and further preferably 1 mg: 12 to 16 mL. The polar organic solvent preferably includes 1,4-dioxane and an ethanol solution; the mass concentration of the ethanol solution is preferably 98%; the volume ratio of the 1,4-dioxane to the ethanol solution is preferably 1: 2.5 to 12, more preferably 1: 5 to 10, and further preferably 1: 6 to 8.
[0061] In the present invention, the mass of the metal salt is preferably 0.5-2% of the mass of the nano manganese dioxide, and more preferably 1.25-1.5%.
[0062] In the present invention, the mixing is preferably carried out under ultrasonic conditions, and the ultrasonic time is preferably 30 minutes.
[0063] In the present invention, the method of removing the organic solvent preferably includes placing the obtained mixture under vacuum conditions until the polar organic solvent is exhausted, and then washing and drying the obtained solid to obtain the drug carrier.
[0064] In the present invention, the washing method is preferably to mix the solid with deionized water and then centrifuge.
[0065] In the present invention, the number of washing is preferably 3 times, and the rotation speed of the centrifugation is preferably 9000 rpm.
[0066] The present invention also provides an embolic microsphere, comprising a degradable skeleton, a drug carrier loaded on the skeleton, and a drug loaded on the drug carrier.
[0067] In the present invention, the mass ratio of the total mass of the drug carrier and the drug to the mass of the degradable skeleton is preferably 1:8-12, more preferably 1:9-10; the mass of the drug is preferably 40-60% of the mass of the drug carrier; the drug preferably includes doxorubicin; and the skeleton preferably includes PLGA.
[0068] The present invention also provides a method for preparing the embolic microspheres described in the above technical solution, comprising the following steps:
[0069] Dispersing the drug carrier loaded with the drug in water and then mixing it with the organic dispersion of the degradable skeleton for emulsification to obtain colostrum;
[0070] The colostrum is mixed with an aqueous solution of an emulsifier, and the water and the organic dispersion solvent are removed to obtain the embolic microspheres.
[0071] The present invention disperses the drug carrier loaded with the drug in water and then mixes it with the organic dispersion of the degradable skeleton for emulsification to obtain colostrum.
[0072] In the present invention, the method for preparing the drug carrier loaded with the drug preferably comprises the following steps:
[0073] The drug, solvent and drug carrier are mixed and then the solvent is removed to obtain the drug carrier loaded with the drug.
[0074] In the present invention, the volume ratio of the mass of the drug to the solvent is preferably 1.5-4 mg:1 mL, more preferably 3-3.5 mg:1 mL; the solvent preferably includes water and ethanol solution; the volume ratio of water and ethanol solution is preferably 1-3:1; the mass concentration of the ethanol solution is preferably 98%.
[0075] In the present invention, the mass of the drug is preferably 45-60% of the mass of the manganese dioxide in the drug carrier, and more preferably 50-55%.
[0076] In the present invention, the mixing temperature is preferably 45 to 55°C, more preferably 48 to 50°C.
[0077] In the present invention, the mixing is preferably carried out under ultrasonic conditions, and the ultrasonic time is preferably 30 minutes.
[0078] In the present invention, the method of removing the solvent preferably includes placing the obtained mixture under vacuum conditions until the solvent is exhausted, and then washing and drying the obtained solid to obtain the drug carrier loaded with the drug.
[0079] In the present invention, the washing method is preferably to mix the solid with deionized water and then centrifuge.
[0080] In the present invention, the number of washing is preferably 3 times, and the rotation speed of the centrifugation is preferably 9000 rpm.
[0081] In the present invention, the ratio of the mass of the drug carrier loaded with drugs to the volume of water is preferably 20 mg:1 mL; the ratio of the mass of the degradable skeleton in the organic dispersion of the degradable skeleton to the volume of the organic dispersant is preferably 50 mg:1 mL.
[0082] In the present invention, the organic dispersion solvent in the organic dispersion of the degradable skeleton preferably includes dichloromethane.
[0083] In the present invention, the emulsification is preferably performed under ultrasonic conditions.
[0084] After obtaining the colostrum, the present invention mixes the colostrum with an aqueous solution of an emulsifier, removes water and an organic dispersion solvent, and obtains the embolic microspheres.
[0085] In the present invention, the volume ratio of the colostrum to the aqueous solution of the emulsifier is preferably 1:100; the mass concentration of the aqueous solution of the emulsifier is preferably 0.05-0.15%, more preferably 0.06-0.12%, further preferably 0.08-0.1%; and the emulsifier is preferably PVA.
[0086] In the present invention, the mixing is preferably performed under stirring conditions.
[0087] The present invention has no particular limitation on the mixing time, as long as the organic dispersing solvent is fully volatilized.
[0088] After the mixing, the method preferably further comprises: filtering the obtained mixture, washing and drying the filtered solid to obtain the embolic microspheres.
[0089] The preparation of the microwave-sensitized drug-loaded microspheres with magnetic resonance visualization provided by the present invention is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0090] Example 1
[0091] (1) Preparation of nano-manganese dioxide loaded with metal salts and doxorubicin (MnO2@(NaCl+DOX))
[0092] Dissolve 70 mL of 0.14 mol / L NaHCO3 and 0.001 mol of MnSO4·H2O in 70 mL of water and stir to form a uniform suspension. Keep at room temperature for 3 hours, centrifuge and wash, take out the precipitate, and dry at 60°C for 6 hours to obtain MnCO3.
[0093] Take 0.1gMnCO3, add it to 20mL of 0.032mol / L KMnO4 solution, stir at a constant speed for 3h at room temperature, and obtain MnO2@MnCO3 with a core-shell structure after centrifugal washing and drying.
[0094] MnO2@MnCO3 was added to 20 mL of 0.1 mol / L dilute HCl and stirred evenly at room temperature for 4 h to remove the MnCO3 template. After centrifugal washing, it was dried at 60 °C for 12 h to finally obtain hollow nano-manganese dioxide, which was recorded as hollow MnO2.
[0095] 1 mg of NaCl, 2 mL of 1,4-dioxane, 10 mL of 98% ethanol solution and 80 mg of hollow MnO2 were added to a 50 mL conical flask. After ultrasonic dispersion for 30 min, the mixed solution was placed under vacuum until the solvent was drained, the obtained solid was mixed with deionized water and centrifuged at 9000 rpm for 10 min, and the mixing and centrifugation were repeated three times. The solid obtained by centrifugation was dried to obtain nano manganese dioxide loaded with NaCl, which was recorded as NaCl@MnO2 nanoparticles.
[0096] A 40 mg dose of doxorubicin DOX, 10 mL of deionized water, 5 mL of 98% ethanol solution and all the prepared NaCl@MnO2 nanoparticles were added to a reactor in a 50°C water bath. After ultrasonic dispersion for 30 minutes, the mixed solution was placed under vacuum conditions until the solvent was drained. The obtained solid was mixed with deionized water and centrifuged at 9000 rpm for 10 minutes. After repeated mixing and centrifugation three times, the solid obtained by centrifugation was dried to obtain nano-manganese dioxide loaded with NaCl and drugs, which were recorded as MnO2@(NaCl+DOX) nanoparticles.
[0097] (2) Preparation of poly(lactic acid-co-glycolic acid) carrier microspheres (PLGA@MnO2@(NaCl+DOX))
[0098] PLGA@MnO2@(NaCl+DOX) microspheres were prepared by double emulsion method:
[0099] 20 mg MnO2@(NaCl+DOX) was dispersed in 1 mL deionized water to form an inner aqueous phase, and 200 mg PLGA was dissolved in 4 mL dichloromethane to form an oil phase. The two were mixed and ultrasonically emulsified for 90 seconds to form colostrum, which was then added to a PVA solution with a mass concentration of 0.1% (external aqueous phase, the volume ratio of colostrum to PVA solution was 1:100). The solution was mechanically stirred for 4 hours to completely evaporate the dichloromethane, filtered, washed with deionized water, and then dried to obtain microspheres (PLGA@MnO2@(NaCl+DOX)).
[0100] Effect demonstration:
[0101] (1) Characterization of PLGA@MnO2@(NaCl+DOX)
[0102] PLGA@MnO2@(NaCl+DOX) was observed by optical microscope and analyzed by scanning electron microscope. Figures 1-2 shown.
[0103] Depend on Figures 1-2 It can be seen that PLGA@MnO2@(NaCl+DOX) is a regular spherical shape.
[0104] The size distribution of PLGA@MnO2@(NaCl+DOX) was statistically analyzed. Figure 3 shown.
[0105] Depend on Figure 3 It can be seen that PLGA@MnO2@(NaCl+DOX) has good dispersibility and the size distribution is between 35 and 65 μm;
[0106] (2) In vitro release of PLGA@MnO2@(NaCl+DOX)
[0107] The PLGA@MnO2@(NaCl+DOX) was placed at 37°C for 20 min and then analyzed by scanning electron microscopy. Figures 4-5 shown. Figure 4 The scale bar is 200 μm. Figure 5 The scale bar is 100 μm.
[0108] Depend on Figures 4-5 It can be seen that at 37°C, the morphology of the microspheres did not change significantly, indicating that the microspheres did not show obvious thermal induction.
[0109] The PLGA@MnO2@(NaCl+DOX) was placed at 65℃ for 20 min and then analyzed by scanning electron microscopy. Figures 6-7 shown. Figure 6 The scale bar is 100 μm. Figure 7 The scale bar is 20 μm.
[0110] Depend on Figures 6-7 It can be seen that at 65°C, the microspheres deformed and ruptured; the above results prove the possibility of temperature-controlled release of MnO2@(DOX+NaCl).
[0111] (3) In vitro sensitization effect of PLGA@MnO2@(NaCl+DOX)
[0112] In order to prove that PLGA@MnO2@(DOX+NaCl) can improve the microwave heating efficiency, 0.1 mg of microspheres were dispersed in 10 mL of saline and the temperature changes were observed after microwave irradiation. Figure 8 shown.
[0113] Depend on Figure 8 It can be seen that compared with pure saline, the material group is 8.95℃ higher, indicating that the material has very good microwave sensitization properties.
[0114] Before the material was used for tumor treatment, hydrogel was used to simulate the in vivo environment. 0.1 mg PLGA@MnO2@(NaCl+DOX) was mixed with 10 g hydrogel (the resulting mixture was recorded as the material group) and then subjected to microwave irradiation. The results were as follows: Fig. 9 shown.
[0115] Depend on Fig. 9 It can be seen that the material group has a better heating effect.
[0116] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A drug carrier, characterized in that The invention comprises hollow nano manganese dioxide and a metal salt loaded on the nano manganese dioxide.
2. The drug carrier according to claim 1, characterized in that The metal salt includes one or more of NaCl, NaF and CaCl2.
3. The drug carrier according to claim 1 or 2, characterized in that The particle size of the nano manganese dioxide is 100-200nm.
4. The drug carrier according to claim 1, characterized in that The mass of the metal salt is 0.5-2% of the mass of the nano manganese dioxide.
5. The method for preparing the drug carrier according to any one of claims 1 to 4, characterized in that: The following steps are involved: The drug carrier is obtained by mixing a metal salt, a polar organic solvent and hollow nano manganese dioxide and removing the polar organic solvent.
6. An embolic microsphere, characterized in that: The invention comprises a degradable skeleton, a drug carrier loaded on the skeleton and a drug loaded on the drug carrier.
7. The embolic microsphere according to claim 6, characterized in that: The drugs include doxorubicin.
8. The embolic microsphere according to claim 6, characterized in that: The backbone includes poly(lactic-co-glycolic acid).
9. The embolic microsphere according to claim 6, characterized in that: The ratio of the total mass of the drug carrier and the drug to the mass of the degradable skeleton is 1:8-12.
10. The method for preparing embolic microspheres according to any one of claims 6 to 9, characterized in that: The following steps are involved: The drug carrier loaded with the drug is dispersed in water and then mixed with the organic dispersion of the degradable skeleton for emulsification to obtain colostrum; The colostrum is mixed with an aqueous solution of an emulsifier, and the water and the organic dispersion solvent are removed to obtain the embolic microspheres.
